Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities.
Excellent balance sheet with moderate growth potential.
Share Price & News
How has Global Blood Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: G5B's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: G5B exceeded the German Biotechs industry which returned 8.4% over the past year.
Return vs Market: G5B exceeded the German Market which returned 13.7% over the past year.
Price Volatility Vs. Market
How volatile is Global Blood Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Global Blood Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: G5B (€66) is trading below our estimate of fair value (€202.06)
Significantly Below Fair Value: G5B is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: G5B is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: G5B is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate G5B's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: G5B is overvalued based on its PB Ratio (6.7x) compared to the DE Biotechs industry average (3.5x).
How is Global Blood Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: G5B is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).
Earnings vs Market: G5B is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: G5B's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if G5B's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if G5B's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: G5B is forecast to be unprofitable in 3 years.
How has Global Blood Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: G5B is currently unprofitable.
Growing Profit Margin: G5B is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: G5B is unprofitable, and losses have increased over the past 5 years at a rate of -39.1% per year.
Accelerating Growth: Unable to compare G5B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: G5B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: G5B has a negative Return on Equity (-33.43%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Global Blood Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: G5B's short term assets ($615.8M) exceed its short term liabilities ($41.2M).
Long Term Liabilities: G5B's short term assets ($615.8M) exceed its long term liabilities ($28.1M).
Debt to Equity History and Analysis
Debt Level: G5B is debt free.
Reducing Debt: G5B has not had any debt for past 5 years.
Inventory Level: G5B has a low level of unsold assets or inventory.
Debt Coverage by Assets: G5B's debt is covered by short term assets (assets are 1.7333313508335E+17x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: G5B has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if G5B has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Global Blood Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate G5B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate G5B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if G5B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if G5B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of G5B's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ted Love (60yo)
Dr. Ted W. Love, M.D., serves as Director at Portola Pharmaceuticals, Inc. since September 2019. Dr. Love is a recognized industry leader with experience in the discovery and development of high impact med ...
CEO Compensation Analysis
Compensation vs Market: Ted's total compensation ($USD10.26M) is above average for companies of similar size in the German market ($USD2.27M).
Compensation vs Earnings: Ted's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||3.8yrs||US$3.33m||0.056% $2.2m|
|Chief Legal Officer & Secretary||3.3yrs||US$3.64m||0.019% $761.5k|
|Chief Business & Strategy Officer||4.8yrs||US$3.28m||0.31% $12.3m|
|Chief Commercial Officer||1.9yrs||US$4.39m||0.022% $871.4k|
|Founder & Advisor||9.1yrs||no data||no data|
|Founder & Advisor||9.1yrs||no data||no data|
|Founder & Advisor||9.1yrs||no data||no data|
|Senior Vice President of Operations||3.4yrs||US$1.44m||no data|
|Senior VP of Finance & Chief Accounting Officer||3.4yrs||no data||0.0055% $220.1k|
Experienced Management: G5B's management team is considered experienced (4.3 years average tenure).
|Lead Independent Director||0yrs||US$441.34k||0.044% $1.7m|
|Independent Director||2.2yrs||US$428.84k||no data|
|Independent Director||4yrs||US$433.84k||no data|
|Independent Director||4.1yrs||US$443.84k||no data|
|Independent Director||1.2yrs||US$743.62k||no data|
Experienced Board: G5B's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.6%.
Global Blood Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Global Blood Therapeutics, Inc.
- Ticker: G5B
- Exchange: DB
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$4.298b
- Listing Market Cap: US$3.981b
- Shares outstanding: 60.23m
- Website: https://www.gbt.com
Number of Employees
- Global Blood Therapeutics, Inc.
- 171 Oyster Point Boulevard
- Suite 300
- South San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GBT||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Aug 2015|
|G5B||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Aug 2015|
|0IVZ||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Aug 2015|
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of voxelotor in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/20 22:40|
|End of Day Share Price||2020/02/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.